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The most noticeable characteristic of politics regarding embry-
onic stem cell (ESC) science is the variety of policy approaches
the subject has engendered. There are hardly two nations that
have the same regulatory scheme for handling ESC research
or clinical trials. Policies range from the complete prohibition of
hESC research (i.e., Ireland, Austria, Lithuania, Poland, Slovakia)
through regulations that allow only certain kinds of research (i.e.,
France, Canada, Germany) to regulations that permit the crea-
tion of embryos for research as well as for therapeutic cloning
(Belgium, China, Singapore, and the United Kingdom). Even
within the United States there is no consensus about what can
and cannot be done, with various states permitting all manner
of stem cell research, such as California, whereas others permit
nothing having to do with embryos or cloning, such as Louisiana.
How did this ethical potpourri come to be? The Global Politics
of Human Embryonic Stem Cell Science sets out to help the
reader understand.
The authors of this very accurately researched book assert
that hESC and cognate fields of regenerative medicine have
become the objects of a kind of global drama. Although biotech-
nology is still mainly regulated by national governments, ‘‘biopo-
litical forces and technological vectors that shape stem cell
science exceed the boundaries of the nation state and involve
regional, transnational and global alliances’’ (p. 5). This said,
the authors deal in eight readily accessible chapters with
different aspects of the narratives that have driven the drama
over the past decade.
The chapters address topics such as national interest in
regenerative medicine, the growing human tissue market, the
problem of global regulation, the role of the cloning of Dolly the
sheep in shaping the regulation of ESC research in different
countries, the role of bioethics in a global moral economy, and
the question of patenting stem cells. Each of the chapters starts
with an introduction and approaches the issue from different
points of view—legal regulation, politics, bioethics, and soci-
ology.
In the first chapter, ‘‘Globalization, Stem Cell Markets and
National Interests,’’ the authors conclude that public investment
in hESC research is very attractive for states because it not only
expresses concern for the well-being of populations but also is
seen as ensuring the global economic competitiveness of the
nation as well. Indeed, much of the rush to corner the market
on hESCs and cloning for research once the Bush administration
put a lid on such activities in the United States was driven by theperceived economic opportunity presented with the United
States essentially out of the game. However, it remains uncertain
whether stem cell research will fulfill the economic promise that
has brought it much attention, investment, and government
support despite ethical concerns.
Chapter two focuses on hESC science and the global market
in human tissues, especially in reproductive tourism—a disturb-
ing phenomenon too often neglected by proponents of embry-
onic stem cell research. The import and export of hESC lines
between nations such as Israel and Germany are discussed in
order to show that there is a tension between proprietary innova-
tion and public domain research on the one hand and a key
dynamic between supply and demand for various biological
materials within a global economy.
Chapters three, four, and five look at the regulation of the
multiple societal, legal, and ethical challenges in stem cell
science. While a single global regime of regulation might be
desirable, the authors make clear that stem cell research, and
if the research proves viable, therapies, must deal with local
policy narratives that lead to inevitable regulatory differences
among nations.
The authors start with the birth of Dolly as the key event in the
local regulatory conflicts around hESC and cloning research.
They ask whether there was any more or less coherent reaction
to the new availability of cloning technologies by the govern-
ments of different countries. They argue that there have been
two basic models to deal with the destabilization of biomedical
and regenerative medicine discourse following Dolly: a coherent
approach involving all the relevant actors in a broadly accepted,
homogenous narrative and an encompassing system of regula-
tion (such as in theUnitedKingdomand in Japan) andaheteroge-
neous regulatory approach emerging within a highly antagonistic
political framework (United States, Germany, Italy) or a system
of repressing the political debate (South Korea). The comparisonCell Stem Cell 5, July 2, 2009 ª2009 Elsevier Inc. 15
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autonomous operation of any cultural patterns can exclusively
explain the regulatory variations. Whereas historical memories
of earlier abuses of science and previous regulatory history
played key roles in the United Kingdom or in Germany, there is
no question that religion was a major factor for the regulatory
pathways chosen in Italy, the United States, and Japan.
Many bioethical institutions were created around the world to
copewith stem cell science and cloning research. Consequently,
in chapters five and six the focus is on bioethics as a ‘‘new
language and practice’’ for dealing with regulatory challenges.
This regulation is characterized by radical moral uncertainty
and a lack of consensus; the boundaries between ‘‘cells,’’ ‘‘the
embryos,’’ and ‘‘human beings’’ and the moral status assigned
to each, such as rights, dignity, and personhood, have been in
a constant state of flux in many countries struggling to shape
stem cell science.
In chapter six, bioethics and its role in the political process are
the focus. Bioethics is seen as a political community, a transna-
tional network, and a bureaucratic device that has become the
political means for the creation of a globalmoral economy.Within
this economy the trading and exchange of values is normalized
and legitimated. Bioethics is, the authors tell us, the ‘‘neutral
currency with which cultural values can be measured, positions
priced and deals arranged’’ (p. 128). The utility of bioethics is its
ability to generate ethical solutions that can be translated into
widely accepted regulatory policy. Cultural values can be con-
tested, but this contest is routinized and assumed to be produc-
tive through the exchange of values under the banner of
bioethics.
While to some degree this interpretation seems true, in that
bioethics speaks neither in explicitly religious terms nor from
a particular normative outlook, it is perhaps not quite as adept
at bridging the cultural and religious divides concerning embryos
and research upon them that exist in many nations. The book
does not give enough credit to the role played by attempts to
offer ‘‘alternatives’’ to the destruction of embryos through
various strategies such as plans to use induced pluripotent cells
to generate a range of adult cell types to treat illnesses and
injuries. Nor do the authors pinpoint the ethical solution that
really did draw some consensus permitting changes in policy
in the United States and other nations—confining the generation
of new stemcell lines to the use of embryos slated for destruction
at infertility clinics. The former was a compromise driven by16 Cell Stem Cell 5, July 2, 2009 ª2009 Elsevier Inc.science. The latter was promptedmore by bioethical argumenta-
tion. Both developments are important in understanding the
evolution of the political debate over stem cells.
Chapter seven focuses on the cultural politics of money spent
on hESC research by the European Union (EU)’s framework
programs. Of particular interest is the bureaucratization of
bioethics and its incorporation as an integral part of decision-
making on project applications for fundingwithin the EU’s frame-
work programs. In this setting bioethics truly did become king.
The authors argue that institutionalized modes of ethics engage-
ment will become a political technology used for stem cells and
other technologies in the future in the EU. The institutionalization
of bioethics in the EU, a phenomena not yet seen in the United
States, China, or India, constitutes a permanent feature of the
new cultural politics of Europe in which bioethics is used to
refine, resolve, and legitimate cultural differences through the
trading of values in an authoritative language and with the clout
to impose answers.
The book ends with a look at the prospects for standardization
of regulations. Regenerative medicine seems to be one of the
first areas of biomedical innovation driven by truly global, socio-
economic, political, and scientific-technological factors. Regen-
erative medicine plays in the transnational arena beyond
confines of any particular province, canton, state, or nation state.
Those scientists who do not like the rules of one province,
canton, state, or nation can head to another. Those nations
who seek to enter into what is seen as a potential economic
driver for their GNP can and do make themselves more hospi-
table to stem cell science. But so do the kooks and crackpots
who fleece the desperately ill with promises all over the Internet
of stem cell ‘‘cures’’ for all manner of diseases. It is not clear how
this rapidly evolving and often inconsistent set of policies can be
reconciled, much less standardized. And maybe it ought not to
be—the authors themselves don’t really take a side. However,
it would seem that the price of letting a hundred regulatory
flowers bloom around the world may be too high to bear in terms
of poor oversight, risk of patient abuse, and a lack of protection
of basic human rights. As stem cell research moves out of its
infancy, perhaps it is time to revisit the regulatory potpourri
that allowed it to be born?
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